CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy

The aim of this study was to evaluate the cartilage intermediate layer protein 1 (CILP1) as a biomarker of right ventricular dysfunction in patients with ischemic cardiomyopathy (ICM). CILP1 plasma concentrations were measured in 98 patients with ICM and 30 controls without any cardiac abnormalities...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary circulation 2022-01, Vol.12 (1), p.e12062-n/a
Main Authors: Keranov, Stanislav, Jafari, Leili, Haen, Saskia, Vietheer, Julia, Kriechbaum, Steffen, Dörr, Oliver, Liebetrau, Christoph, Troidl, Christian, Rutsatz, Wiebke, Rieth, Andreas, Hamm, Christian W., Nef, Holger, Rolf, Andreas, Keller, Till
Format: Article
Language:English
Subjects:
Biomarkers
Cardiomyopathy
Ejection fraction
fibrosis
Ischemia
MRI
myocardial remodeling
RVEF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate the cartilage intermediate layer protein 1 (CILP1) as a biomarker of right ventricular dysfunction in patients with ischemic cardiomyopathy (ICM). CILP1 plasma concentrations were measured in 98 patients with ICM and 30 controls without any cardiac abnormalities. All participants underwent cardiac magnetic resonance imaging. Median CILP1 concentrations were higher in ICM than in controls. In the tertile analysis, low right ventricular ejection fraction (RVEF) and high right ventricular end‐systolic volume index and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) were associated with higher CILP1 levels in ICM. However, there were no associations between CILP1 concentrations and left ventricular (LV) parameters in this group. In receiver‐operating characteristic (ROC) analysis CILP1 was a good predictor of RVEF 
ISSN:2045-8940
2045-8932
2045-8940
DOI:10.1002/pul2.12062